Underlying Causes
Primary biliary cholangitis is considered an autoimmune disease. This means the body's immune system, which usually fights infection, mistakenly turns against its own cells. In this condition, T cells accumulate in the liver and destroy the epithelial cells lining the small bile ducts. When these ducts are damaged, bile cannot flow out of the liver properly. The retained bile acts like a toxin to the liver cells, causing inflammation and scarring (fibrosis). While the exact trigger for this immune response is unknown, researchers believe it involves a combination of genetic predisposition and environmental factors.

Risk Factors
Several factors increase the likelihood of developing this condition. Biological sex is the strongest risk factor, as women are affected significantly more often than men. Age is another factor, with diagnosis typically occurring between 30 and 60 years of age. Genetics play a role, so having a parent or sibling with the condition slightly increases risk. Environmental factors that may trigger the disease in susceptible individuals include smoking, exposure to certain chemicals or toxins, and urinary tract infections. It is also more common in people who have other autoimmune conditions, such as autoimmune thyroid disease, Sjögren’s syndrome, or Raynaud’s phenomenon.

Prevention
There is no known way to prevent primary biliary cholangitis because the exact cause remains unclear. Strategies focus on secondary prevention, which involves stopping the progression of the disease once it starts. However, reducing modifiable risk factors like smoking may be beneficial for general liver health. Because the condition is not caused by alcohol or diet, lifestyle changes alone cannot prevent the onset of the autoimmune process.

Common Signs and Symptoms
Many people with primary biliary cholangitis have no symptoms when they are first diagnosed, often finding out through routine blood tests. When symptoms do appear, the most common are fatigue and pruritus (itchy skin). The itching can be intense, often affecting the hands and feet or the whole body, and worsens at night. Other common symptoms include dry eyes and dry mouth (sicca syndrome). As the disease progresses, individuals may experience pain in the upper right abdomen, darkening of the skin (hyperpigmentation), or small yellow bumps of fat under the skin around the eyes (xanthomas).

Complications and Advanced Symptoms
If the liver damage becomes severe, signs of cirrhosis may develop. These include jaundice (yellowing of the skin and whites of the eyes), swelling in the legs (edema) or abdomen (ascites), and easy bruising or bleeding. The condition also affects bone health, leading to weak or brittle bones (osteoporosis), which increases the risk of fractures.

Diagnostic Tests
Doctors typically suspect the condition based on abnormal blood tests, specifically elevated levels of the liver enzyme alkaline phosphatase (ALP). To confirm the diagnosis, they test for anti-mitochondrial antibodies (AMAs), which are present in the vast majority of people with this condition. If AMAs are negative but liver enzymes are high, a liver biopsy may be performed to examine the liver tissue for characteristic signs of bile duct damage. Imaging tests like ultrasound or magnetic resonance cholangiopancreatography (MRCP) are often used to rule out other causes of bile duct obstruction.

Differential Diagnosis
Clinicians must differentiate this condition from other liver diseases. These include primary sclerosing cholangitis, which affects larger bile ducts; autoimmune hepatitis; and drug-induced liver injury. It is also distinct from alcohol-associated liver disease and metabolic dysfunction-associated steatotic liver disease.

Medications
The first-line treatment for primary biliary cholangitis is ursodeoxycholic acid (UDCA), also known as ursodiol. This is a naturally occurring bile acid that helps move bile through the liver and reduces liver inflammation. When taken early, UDCA can slow disease progression and prevent liver damage in many patients. For individuals who do not respond fully to UDCA, second-line therapies such as obeticholic acid or fibrates may be prescribed to further lower liver enzyme levels. These medications address the underlying disease process rather than just symptoms.

Symptom Management
Managing the side effects of the condition is a key part of treatment. For severe itching (pruritus), doctors may prescribe bile acid sequestrants like cholestyramine, or other medications such as rifampin, naltrexone, or sertraline. Dry eyes and mouth are often managed with artificial tears and saliva substitutes. Vitamin supplements are frequently necessary because the body may have trouble absorbing fat-soluble vitamins (A, D, E, and K) due to reduced bile flow.

Procedures and Surgery
In advanced cases where medications are no longer effective and liver function is severely compromised, a liver transplant may be the best option. Liver transplantation is highly successful for this condition, often restoring health and quality of life. Recurrence of the disease in the new liver is possible but typically progresses very slowly.

Lifestyle and Self-Care
Patients are encouraged to avoid alcohol, as it adds stress to the liver. Maintaining a healthy weight and eating a balanced diet helps prevent fatty liver disease, which could complicate the condition. Because osteoporosis is a risk, weight-bearing exercises and calcium/vitamin D supplementation are important for bone health.

When to Seek Medical Care
Regular monitoring is essential to track liver enzymes and disease progression. Patients should see a doctor if they notice new or worsening symptoms, particularly persistent itching, yellowing of the skin or eyes, swelling in the abdomen or legs, or blood in the stool or vomit. Immediate medical attention is required for confusion, severe abdominal pain, or vomiting blood, which can indicate serious complications of liver disease.

Severity Levels
Primary biliary cholangitis varies widely in severity. Some individuals remain asymptomatic for decades, while others experience rapid progression. The disease is generally categorized by stages of liver damage, ranging from early inflammation to fibrosis (scarring) and finally cirrhosis (severe scarring). The severity is often monitored through blood tests measuring alkaline phosphatase and bilirubin levels.

Disease Course and Prognosis
The outlook for people with this condition has improved significantly with modern treatments. Most patients diagnosed early and treated with ursodeoxycholic acid (UDCA) have a life expectancy similar to the general population. The disease course is chronic and slow-moving. However, prognosis is less favorable for those who do not respond to medication or who are diagnosed at a late stage where significant liver scarring has already occurred. Factors indicating a more serious course include high bilirubin levels, low albumin, and lack of biochemical response to treatment.

Complications
Long-term complications are primarily related to chronic cholestasis and cirrhosis. Malabsorption of fats can lead to deficiencies in vitamins A, D, E, and K. Osteoporosis is a significant risk, leading to brittle bones. In the advanced cirrhosis stage, complications include portal hypertension (high pressure in the liver vein), esophageal varices (enlarged veins in the throat that can bleed), and an increased risk of liver cancer (hepatocellular carcinoma). Regular screening helps manage these risks effectively.

Managing Daily Activities
Living with primary biliary cholangitis often means managing energy levels. Fatigue is a major complaint and does not necessarily correlate with the severity of liver damage. Patients may need to pace themselves, prioritize tasks, and take short naps. Itching can also disrupt sleep, leading to further exhaustion during the day, so treating the itch is vital for maintaining daily function.

Mental and Emotional Health
The uncertainty of a chronic progressive disease can lead to anxiety or depression. Coping with visible symptoms like jaundice or the discomfort of constant itching can also affect self-esteem and social interactions. Support groups, whether in-person or online, can be valuable resources for connecting with others who understand the specific challenges of this condition.

Questions to Ask Your Healthcare Provider

• What stage is my liver disease currently in?
• Am I responding well to my current dosage of ursodeoxycholic acid?
• What specific diet or lifestyle changes will best support my liver health?
• How often do I need blood tests and imaging scans?
• What are the side effects of the medications prescribed for itching?
• Should I be taking supplements for calcium or Vitamin D?
• Are there any new treatments or clinical trials I should consider?
• What signs of progression should I watch for at home?

Q: Is primary biliary cholangitis contagious?
A: No, primary biliary cholangitis is an autoimmune disease. It cannot be spread from person to person through contact, coughing, or sharing food.

Q: Did alcohol cause this condition?
A: No, this condition is not caused by alcohol consumption. It is distinct from alcohol-associated liver disease, although patients are advised to avoid alcohol to protect the liver from additional stress.

Q: Why was the name changed from primary biliary cirrhosis?
A: The name was changed to primary biliary cholangitis because "cirrhosis" implies advanced liver scarring. Many patients are diagnosed early when they do not have cirrhosis, so the old name was confusing and unnecessarily alarming.

Q: Can I still get pregnant if I have this condition?
A: Yes, many women with primary biliary cholangitis have successful pregnancies. However, it is important to discuss pregnancy plans with a specialist, as liver enzyme levels need monitoring and some medications may need adjustment.

Q: Will I definitely need a liver transplant?
A: Not necessarily. Many people managed with medication early in the disease course never progress to the point of needing a transplant. Transplantation is reserved for end-stage liver disease.